TABLE 1

Clinical characteristics of STZ-induced DR, DR+I, DR+I/P, or DR+I/E

nBody weight (g)24-h urine volume (ml)Blood glucose (mmol/l)Average dose of insulin (unit)
CR7346.3 ± 9.419.1 ± 0.84.7 ± 0.2
DR6237.1 ± 18.3*120.4 ± 20.1*26.9 ± 0.6*
DR + I7342.2 ± 5.849.2 ± 11.114.3 ± 1.3*5.5 ± 0.8
DR + I/P6318.8 ± 8.325.7 ± 4.012.7 ± 2.1*6.5 ± 0.7
DR + I/E7323.4 ± 6.431.9 ± 6.016.5 ± 2.5*6.3 ± 0.4
  • Values are means ± SE. Diabetes in rats was induced by intraperitoneal injection of 60 mg/kg STZ. For insulin treatment, daily subcutaneous injection of intermediate-acting insulin (target blood glucose 11.1 to ∼16.7 mmol/l) was given at 4:00 p.m. from the 3rd day after administration of STZ for 4 weeks. DR + I/P had subcutaneous insulin and probucol (1% wt/wt) in diet. DR + I/E had subcutaneous insulin and vitamin E–enriched diet (100 IU/kg food wt).

  • *

    * P < 0.005 vs. CR,

  • P < 0.005 vs. DR.